Novel351k

Novel351k

Biotechnology, 2300 Englert Dr, , Illinois, New Jersey, 27713, United States, 1-10 Employees

351k.com

  • LinkedIn

phone no Phone Number: +19*********

Who is NOVEL351K

Innovative and flexible technology for rapid and cost-effective approval of biosimilars to market. With over 30 years of experience in creating new drugs, chemicals, biologicals, and bios...

Read More

map
  • 2300 Englert Dr, New Jersey, Illinois, 27713, United States Headquarters: 2300 Englert Dr, New Jersey, Illinois, 27713, United States
  • 1-10 Employees: 1-10
  • dollar-icon Revenue: $250 Million to $500 Million

industries-icon Industry: Biotechnology

SIC SIC Code: 2836 | NAICS Code: 541714 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from NOVEL351K

Novel351k Org Chart and Mapping

Employees
signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding Novel351k

Answer: Novel351k's headquarters are located at 2300 Englert Dr, , Illinois, New Jersey, 27713, United States

Answer: Novel351k's phone number is +19*********

Answer: Novel351k's official website is https://351k.com

Answer: Novel351k's revenue is $250 Million to $500 Million

Answer: Novel351k's SIC: 2836

Answer: Novel351k's NAICS: 541714

Answer: Novel351k has 1-10 employees

Answer: Novel351k is in Biotechnology

Answer: Novel351k contact info: Phone number: +19********* Website: https://351k.com

Answer: Innovative and flexible technology for rapid and cost-effective approval of biosimilars to market. With over 30 years of experience in creating new drugs, chemicals, biologicals, and biosimilars, we are now creating a novel platform that guarantees the lowest cost and time to market-We guarantee it. Novel 351k provides innovative and flexible technology for rapid and cost-effective approval of biosimilars to market. We provide innovation and speed to existing commercial models that reduce the time for pharma and biotech partners to manage their portfolios and development costs efficiently and effectively by bringing approved biosimilars to the process of licensing stages the market more rapidly. Our core strength is complemented by decades of experience working through the novelty of the regulatory path.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access